Second line chemotherapy with irinotecan (CPT-11) and mitomycin-C (MMC) in patients with advanced/metastatic colorectal (CC) and gastric cancer (GC): A phase II trial.

被引：0
|
作者：
Papamichael, D
Bamias, A
Ioannides, G
Syrigos, K
Demosthenous, C
Pavlidis, N
机构：
[1] Univ Athens, Sotiria Hosp, Dept Med 3, Athens, Greece
[2] Ioannina Univ Hosp, Ioannina, Greece
[3] BO Cyprus Oncol Ctr, Nicosia, Cyprus
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
250
引用
收藏
页码：57 / 57
页数：1
相关论文
共 50 条
  • [1] The efficacy of irinotecan (CPT-11) and mitomycin C (MMC) as second line chemotherapy: Preliminary report of a phase II trial in gastric cancer
    Tadaoka, N
    Inomata, Y
    Nakamura, Y
    Sakuyama, T
    Takahashi, N
    Otani, M
    Takayama, S
    Aoki, T
    PROGRESS IN GASTRIC CANCER RESEARCH 1997: PROCEEDINGS OF THE 2ND INTERNATIONAL GASTRIC CANCER CONGRESS, 1997, : 1571 - 1573
  • [2] Irinotecan (CPT-11) and mitomycin-C (MMC) as second line treatment in advanced gastric cancer patients. A phase II study of the gruppo oncologico dell'italia meridionale (GOIM)
    Giuliani, F.
    Maiello, E.
    Molica, S.
    Gebbia, N.
    Di Bisceglie, M.
    Battaglia, C.
    Vinciarelli, G.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2005, 16 : 157 - 157
  • [3] Irinotecan (CPT-11) and Mitomycin-C (MMC) as second-line treatment in advanced gastric cancer patients. A phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
    Giuliani, F
    Maiello, E
    Molica, S
    Battaglia, C
    Gebbia, N
    Di Bisceglie, M
    Vinciarelli, G
    Colucci, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 372S - 372S
  • [4] IRINOTECAN (CPT-11) AND MITOMYCIN-C (MMC) AS SECOND-LINE TREATMENT IN ADVANCED GASTRIC CANCER (AGC) PATIENTS. A PHASE II STUDY OF THE GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE (GOIM)
    Giuliani, F.
    Maiello, E.
    Molica, S.
    Gebbia, N.
    Di Bisceglie, M.
    Battaglia, C.
    Vinciarelli, G.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2004, 15 : 76 - 76
  • [5] Irinotecan (CPT-11) plus mitomycin C (MMC) for the second line treatment of patients (PTS) with advanced colorectal carcinoma (ACC). A phase I/II study.
    Casaretti, R
    Biglietto, M
    De Lucia, L
    De Cataldis, G
    Di Lullo, L
    Maiorino, L
    Avallone, A
    Guarrasi, R
    Comella, P
    Comella, G
    ANNALS OF ONCOLOGY, 2000, 11 : 65 - 65
  • [6] Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer
    J. Cassinello
    P. López-Alvarez
    A. Martínez-Guisado
    M. Valladares
    G. Huidobro
    R. López
    U. Bohn
    I. Sevilla
    P. Ballesteros
    M. Jorge
    R. Pérez-Carrión
    J. L. Fernández
    J. Dorta
    Medical Oncology, 2003, 20 : 37 - 43
  • [7] Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer
    Cassinello, J
    López-Alvarez, P
    Martínez-Guisado, A
    Valladares, M
    Huidobro, G
    López, R
    Bohn, U
    Sevilla, I
    Ballesteros, P
    Jorge, M
    Pérez-Carrión, R
    Fernández, JL
    Dorta, J
    MEDICAL ONCOLOGY, 2003, 20 (01) : 37 - 43
  • [8] Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)
    Mrozek, E.
    Kolesar, J.
    Young, D.
    Allen, J.
    Villalona-Calero, M.
    Shapiro, C. L.
    ANNALS OF ONCOLOGY, 2008, 19 (08) : 1417 - 1422
  • [9] A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer
    Heather Wakelee
    George A. Fisher
    Investigational New Drugs, 2005, 23 : 241 - 242
  • [10] A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer
    Wakelee, H
    Fisher, GA
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (03) : 241 - 242
12345